nach oben

Erschienen in:

01.01.2013 | Original article

Stereotactic ablative radiotherapy for small lung tumors with a moderate dose

Favorable results and low toxicity

verfasst von: V. Duncker-Rohr, MD, U. Nestle, MD, PhD, F. Momm, MD, PhD, V. Prokic, PhD, F. Heinemann, MD, M. Mix, PhD, J. Reusch, MD, M.-B. Messmer, MD, N. Marschner, MD, C.F. Waller, MD, PhD, W.A. Weber, MD, PhD, A.-L. Grosu, MD, PhD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Stereotactic ablative body radiotherapy (SBRT, SABR) is being increasingly applied because of its high local efficacy, e.g., for small lung tumors. However, the optimum dosage is still under discussion. Here, we report data on 45 lung lesions [non-small cell lung cancer (NSCLC) or metastases] in 39 patients treated between 2009 and 2010 by SABR.

Patients and methods

SABR was performed with total doses of 35 Gy (5 fractions) or 37.5 Gy (3 fractions) prescribed to the 60% isodose line encompassing the planning target volume. Three-monthly follow-up CT scans were supplemented by FDG-PET/CT if clinically indicated.

Results

The median follow-up was 17 months. Local progression-free survival rates were 90.5% (all patients), 95.0% (NSCLC), and 81.8% (metastases) at 1 year. At 2 years, the respective local progression-free survival rates were 80.5%, 95.0%, and 59.7%. Overall survival rates were 71.1% (all patients), 65.4% (NSCLC), and 83.3% (metastases) at 1 year. Overall survival rates at 2 years were 52.7%, 45.9%, and 66.7%, respectively. Acute side effects were mild.

Conclusion

With the moderate dose schedule used, well-tolerated SABR led to favorable local tumor control as in other published series. Standardization in reporting the dose prescription for SABR is needed to allow comparison of different series in order to determine optimum dosage.

Loo BW et al (2011) Stereotactic ablative radiotherapy: what’s in a name? Practical Radiat Oncol 1:38–39CrossRef

Crabtree TD et al (2010) Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 140:377–386PubMedCrossRef

Grills IS et al (2010) Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 28:928–935PubMedCrossRef

Haasbeek CJ et al (2010) Stage I nonsmall cell lung cancer in patients aged > or = 75 years: outcomes after stereotactic radiotherapy. Cancer 116:406–414PubMedCrossRef

Lagerwaard FJ et al (2008) Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 70:685–692PubMedCrossRef

Nguyen NP et al (2008) Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma. Cancer Treat Rev 34:719–727PubMedCrossRef

Onishi H et al (2010) Stereotactic Body Radiotherapy (SBRT) for operable stage i non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys 81:1352–1358PubMedCrossRef

Timmerman RD et al (2009) Local surgical, ablative, and radiation treatment of metastases. CA Cancer J Clin 59:145–170PubMedCrossRef

Palma D et al (2010) Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol 28:5153–5159PubMedCrossRef

10.

Timmerman R et al (2007) Optimizing dose and fractionation for stereotactic body radiation therapy. Normal tissue and tumor control effects with large dose per fraction. Front Radiat Ther Oncol 40:352–365PubMedCrossRef

11.

Onishi H et al (2007) Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2 [7 Suppl 3]:S94–S100

12.

Hiraoka M, Nagata Y (2004) Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the Japanese experience. Int J Clin Oncol 9:352–355PubMedCrossRef

13.

Zhang J et al (2011) Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis. Int J Radiat Oncol Biol Phys 81:305–316CrossRef

14.

McGarry RC et al (2005) Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys 63:1010–1015PubMedCrossRef

15.

Guckenberger M et al (2009) Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys 74:47–54PubMedCrossRef

16.

Wurstbauer K et al (2010) Non-small cell lung cancer in stages I-IIIB: Long-term results of definitive radiotherapy with doses >/= 80 Gy in standard fractionation. Strahlenther Onkol 186:551–557PubMedCrossRef

17.

Chang BK, Timmerman RD (2007) Stereotactic body radiation therapy: a comprehensive review. Am J Clin Oncol 30:637–644PubMedCrossRef

18.

Dahele M et al (2009) Stereotactic radiation therapy for inoperable, early-stage non-small-cell lung cancer. CMAJ 180:1326–1328PubMedCrossRef

19.

Heinzerling JH, Kavanagh B, Timmerman RD (2011) Stereotactic ablative radiation therapy for primary lung tumors. Cancer J 17:28–32PubMedCrossRef

20.

Siva S, MacManus M, Ball D (2010) Stereotactic radiotherapy for pulmonary oligometastases: a systematic review. J Thorac Oncol 5:1091–1099PubMed

21.

Zimmermann FB et al (2005) Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer. Lung Cancer 48:107–114PubMedCrossRef

22.

Lammering G et al (2010) The use of FDG-PET to target tumors by radiotherapy. Strahlenther Onkol 186:471–481PubMedCrossRef

23.

Hodapp N et al (2009) The Freiburg patient positioning and fixation concept for precision radiotherapy. Strahlenther Onkol 185:126

24.

Boda-Heggemann J et al (2011) kV cone-beam CT-based IGRT: a clinical review. Strahlenther Onkol 187:284–291PubMedCrossRef

25.

Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef

26.

Young H et al (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35:1773–1782PubMedCrossRef

27.

NIH and NCI (2009) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. available on http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40

28.

Andratschke N et al (2011) Stereotactic radiotherapy of histologically proven inoperable stage I non-small cell lung cancer: patterns of failure. Radiother Oncol 101:245–249PubMedCrossRef

29.

Wulf J et al (2004) Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys 60:186–196PubMedCrossRef

30.

Timmerman R et al (2003) Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 124:1946–1955PubMedCrossRef

31.

Bradley JD et al (2010) Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant. Int J Radiat Oncol Biol Phys 77:1146–1150PubMedCrossRef

32.

Oshiro Y et al (2010) Stereotactic body radiotherapy for lung tumors at the pulmonary hilum. Strahlenther Onkol 186:274–279PubMedCrossRef

33.

Baardwijk A van et al (2011) What is the radiation dose needed to eradicate stage I NSCLC with Stereotactic Radiotherapy (SBRT)? J Thorac Oncol 6:544

34.

Hoppe BS et al (2008) Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: who’s at risk? Int J Radiat Oncol Biol Phys 72:1283–1286PubMedCrossRef

35.

Borst GR et al (2009) Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy. Radiother Oncol 91:307–313PubMedCrossRef

36.

Jin JY et al (2009) Impact of fraction size on lung radiation toxicity: hypofractionation may be beneficial in dose escalation of radiotherapy for lung cancers. Int J Radiat Oncol Biol Phys 76:782–788PubMedCrossRef

37.

Takeda A et al (2010) Early graphical appearance of radiation pneumonitis correlates with the severity of radiation pneumonitis after stereotactic body radiotherapy (SBRT) in patients with lung tumors. Int J Radiat Oncol Biol Phys 77:685–690PubMedCrossRef

38.

Hamamoto Y et al (2011) Relationship between pretreatment FDG uptake and local control after stereotactic body radiotherapy in stage I non-small-cell lung cancer: the preliminary results. Jpn J Clin Oncol 41:543–547PubMedCrossRef

39.

Nestle U et al (2009) Biological imaging in radiation therapy: role of positron emission tomography. Phys Med Biol 54:R1–R25PubMedCrossRef

40.

Waarde A van et al (2004) Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 45:695–700PubMed

41.

Vansteenkiste J, Dooms C (2007) Positron emission tomography in nonsmall cell lung cancer. Curr Opin Oncol 19:78–83PubMedCrossRef

42.

Baardwijk A van et al (2008) Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: a feasibility study. Int J Radiat Oncol Biol Phys 71:1394–1401PubMedCrossRef

Titel: Stereotactic ablative radiotherapy for small lung tumors with a moderate dose
Favorable results and low toxicity
verfasst von: V. Duncker-Rohr, MD
U. Nestle, MD, PhD
F. Momm, MD, PhD
V. Prokic, PhD
F. Heinemann, MD
M. Mix, PhD
J. Reusch, MD
M.-B. Messmer, MD
N. Marschner, MD
C.F. Waller, MD, PhD
W.A. Weber, MD, PhD
A.-L. Grosu, MD, PhD
Publikationsdatum: 01.01.2013
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 1/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-012-0224-y

Springer Medizin

Stereotactic ablative radiotherapy for small lung tumors with a moderate dose

Favorable results and low toxicity